![]() |
| Home | Articles | Resources | About us | Quick Tips | Educational materials |
|
Find us again! Moodletter provides information, hope and help to people living with depression, anxiety or bipolar disorder and those who care for them. ©2006-2011 Deborah Wiig
|
Use of atypical antipsychotic drugs increases
|
Have
you read these?
|
|||||||||||
Patients ages 30 to 74 who took atypical antipsychotics such as risperidone (sold as Risperdal), quetiapine (Seroquel), olanzapine (Zyprexa) and clozapine (Clozaril) had a significantly higher risk of sudden death from cardiac arrhythmias and other cardiac causes than patients who did not take these medications, according to a new study funded by the Department of Health & Human Services' (HHS) Agency for Healthcare Research and Quality (AHRQ). The risk of death increased with higher doses of the drugs taken. The study, titled "Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death," is published in the January 15, 2009 issue of the New England Journal of Medicine. Atypical antipsychotics are commonly used to treat schizophrenia and bipolar disorders. They are also prescribed "off label" for symptoms such as agitation, anxiety, psychotic episodes and obsessive behaviors. Atypical antipsychotics are less likely to cause tremors and other serious movement disorders that affect users of typical antipsychotics. "This study provides critical information about the safety of atypical antipsychotics that can be used to make important treatment decisions for patients," said AHRQ Director Carolyn M. Clancy, M.D. "These findings will help clinicians and patients weigh the risks versus the benefits of these drugs before prescribing them for treatment of depression or other off label uses for other conditions." |
|
Related articles Source Page updated February 1, 2009
|
|||||||||||